South-South entrepreneurial collaboration in health biotech

  • An Erratum to this article was published on 07 December 2010

A survey of entrepreneurial collaborations among health biotech firms in developing countries reveals a surprisingly high level of collaboration but a lack of emphasis on new or improved health biotech products and processes.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2
Figure 3: Collaboration network of health biotech firms in South-South collaborations.
Figure 4
Figure 5: The network of collaborations involving end-stage commercialization versus R&D.

Change history

  • 07 December 2010

    In the version of this article initially published, a line was missing connecting India and China in Figure 3. The error has been corrected in the HTML and PDF versions of the article.


  1. 1

    Anonymous. South-south trade: vital for development (Policy brief) (Organisation for Economic Co-Operation and Development, Paris, 2006)

  2. 2

    Anonymous. Global economic prospects: crisis, finance, and growth (The International Bank for Reconstruction and Development & The World Bank, Washington, DC, 2010)

  3. 3

    Hassan, M.H. Building capacity in the life sciences in the developing world. Cell 131, 433–436 (2007).

  4. 4

    Mkoka, C. South African scientists welcome Malawi on board. SciDev.Net (17 August 2007).

  5. 5

    Thorsteinsdóttir, H., Quach, U., Daar, A.S. & Singer, P.A. Conclusions: promoting biotechnology innovation in developing countries. Nat. Biotechnol. 22 suppl., DC48–DC52 (2004).

  6. 6

    Frew, S.E. et al. India's health biotech sector at a crossroads. Nat. Biotechnol. 25, 403–417 (2007).

  7. 7

    Frew, S.E. et al. Chinese health biotech and the three-billion patient market. Nat. Biotechnol. 26, 37–53 (2008).

  8. 8

    Rezaie, R. et al. Brazilian health biotech – fostering crosstalk between public and private sectors. Nat. Biotechnol. 26, 627–644 (2008).

  9. 9

    Al-Bader, S. et al. Small but tenacious: South Africa's health biotech sector. Nat. Biotechnol. 27, 427–445 (2009).

  10. 10

    Morel, C.M. et al. Health innovation networks to help developing countries address neglected diseases. Science 309, 401–404 (2005).

  11. 11

    Lemle, M. Nations team up to share R & D skills in HIV/AIDS battle. SciDev.Net (28 February 2005)

  12. 12

    Ohiorhenuan, J.F.E. & Rath, A. in Desigining the Future: South-South Cooperation in Science and Technology (eds. Zhou, Y. & Gitta, C.) (United Nations Development Programme, New York, 2000)

  13. 13

    Pisano, G.P. Science Business: The Promise, the Reality, and the Future of Biotech (Harvard Business School Press, Boston, 2006)

  14. 14

    Hagedoorn, J. Inter-firm R&D partnerships: an overview of major trends and patterns since 1960. Res. Policy 31, 477–492 (2002).

  15. 15

    Faulkner, W. & Senker, J. Knowledge Frontiers: Public Sector Research and Industrial Innovation in Biotechnology, Engineering Ceramics and Parallel Computing (Oxford University Press, 1995).

  16. 16

    Lee, C.W. Strategic alliances influence on small and medium firm performance. J. Bus. Res. 60, 731–741 (2007).

  17. 17

    Roijakkers, N. & Hagedoorn, J. Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks. Res. Policy 35, 431–446 (2006).

  18. 18

    van Beuzekom, B. & Arundel, A. OECD biotechnology statistics (Organisation for Economic Co-Operation and Development, Paris, 2006).

  19. 19

    Yusuf, S., Nabeshima, K. & Perkins, D. in Dancing with Giants: China, India and the Global Economy (eds. Winteres, L.A. & Ysuf, S.) 35–66 (The World Bank, Washington, DC, and the Institute of Policy Studies, Singapore, 2007).

  20. 20

    Chaturvedi, K., Chataway, J. & Wield, D. Policy, markets and knowledge: strategic synergies in Indian pharmaceutical firms. Technol. Anal. Strateg. Manage. 19, 565–588 (2007).

  21. 21

    Bower, D.J. & Sulej, J.C. The Indian challenge: the evolution of a successful new global strategy in the pharmaceutical industry. Technol. Anal. Strateg. Manage. 19, 611–624 (2007).

  22. 22

    Maiti, R. & Raghavendra, M. Clinical trials in India. Pharmacol. Res. 56, 1–10 (2007).

  23. 23

    Ray, M., Daar, A.S., Singer, P.A. & Thorsteinsdóttir, H. Globetrotting firms. a survey of Canada's health biotechnology collaboration with developing countries. Nat. Biotechnol. 27, 806–814 (2009).

  24. 24

    Kale, D. & Little, S. From imitation to innovation: the evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry. Technol. Anal. Strateg. Manage. 19, 589–609 (2007).

  25. 25

    Simonetti, R. & Archambault, E. The dynamics of pharmaceutical patenting in India: evidence from USPTO data. Technol. Anal. Strateg. Manage. 19, 625–642 (2007).

  26. 26

    Thorsteinsdóttir, H. The role of the health system in health biotechnology in developing countries. Technol. Anal. Strateg. Manage. 19, 659–675 (2007).

  27. 27

    Taylor, A.D. et al. North–South partnerships—a study of Canadian firms. Nat. Biotechnol. 25, 978–979 (2007).

  28. 28

    Sangkitporn, S. et al. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients. Southeast Asian J. Trop. Med. Public Health 36, 704–708 (2005).

Download references


The authors thank all the firms that responded to the survey and generously shared their expertise and time. We also thank J. Clark and K. MacDonald for comments on the manuscript. This project was funded by Genome Canada through the Ontario Genomics Institute and by the International Development Research Centre, and was supported by the McLaughlin-Rotman Centre for Global Health, an academic center at the University Health Network and University of Toronto. H.T. is supported by a New Investigator Award from the Canadian Institutes of Health Research. M.R. is supported by a Canadian Institutes of Health Research Training Award.

Author information

Correspondence to Halla Thorsteinsdóttir.

Ethics declarations

Competing interests

P.A.S. has received consulting funds from Merck Frosst Canada and is on the scientific advisory board of the Bioveda II fund in China.

Supplementary information

Supplementary Text and Figures

Supplementary Methods (PDF 63 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thorsteinsdóttir, H., Melon, C., Ray, M. et al. South-South entrepreneurial collaboration in health biotech. Nat Biotechnol 28, 407–416 (2010) doi:10.1038/nbt0510-407

Download citation

Further reading